
Late effects after breast cancer treatment

CLINICAL REVIEW

KATHRINE F. VANDRAAS

katvan@ous-hf.no

National Advisory Unit for Late Effects after Cancer Treatment

Oslo University Hospital

and

Breast Oncology Section

Division of Cancer Medicine

Oslo University Hospital

Author contribution: concept, literature search, design of the first draft of the manuscript, and revision and approval of the submitted version.

Kathrine F. Vandraas, specialist in oncology, senior consultant and postdoctoral fellow.

The author has completed the ICMJE form and declares the following conflict of interest: She has received research support from the Norwegian Pink Ribbon Foundation.

SOLVEIG SMEDSLAND

National Advisory Unit for Late Effects after Cancer Treatment

Division of Cancer Medicine

Oslo University Hospital

Author contribution: drafting and revision of the manuscript, and approval of the submitted version.

Solveig Smedsland, specialist in oncology, senior consultant and PhD research fellow.

The author has completed the ICMJE form and declares the following conflict of interest: She has received research support from the Norwegian Pink Ribbon Foundation.

HARALD KÅRE ENGAN

Unicare Norge, Oslo

Author contribution: drafting and revision of the manuscript, and approval of the submitted version.

Harald Kåre Engan, PhD, senior researchers and head of Research and Development (R&D).

The author has completed the ICMJE form and declares the following conflicts of interest: He has received research support from the Norwegian Pink Ribbon Foundation and the Norwegian Cancer Society.

CECILIE KISERUD

National Advisory Unit for Late Effects after Cancer Treatment
Division of Cancer Medicine
Oslo University Hospital

Author contribution: drafting and revision of the manuscript, and approval of the submitted version.

Cecilie Kiserud, senior consultant and head of the National Advisory Unit for Late Effects after Cancer Treatment.

The author has completed the ICMJE form and declares the following conflicts of interest: She has received research support from the Norwegian Pink Ribbon Foundation and the Norwegian Cancer Society.

BJØRN NAUME

Breast Oncology Section
Division of Cancer Medicine
Oslo University Hospital
and
Institute of Clinical Medicine
University of Oslo

Author contribution: drafting and revision of the manuscript, and approval of the submitted version.

Bjørn Naume, senior consultant and professor. He is head of the Norwegian Breast Cancer Group.

The author has completed the ICMJE form and declares the following conflicts of interest: He has received research support from the Norwegian Pink Ribbon Foundation and the Norwegian Cancer Society.

METTE BREKKE

Department of General Practice
Institute of Health and Society
University of Oslo

Author contribution: drafting and revision of the manuscript, and approval of the submitted version.

Mette Brekke, specialist in general practice and professor.

The author has completed the ICMJE form and declares no conflicts of interest.

KRISTIN VALBORG REINERTSEN

National Advisory Unit for Late Effects after Cancer Treatment

and

Breast Oncology Section

Division of Cancer Medicine

Oslo University Hospital

Author contribution: concept, literature search, design of the first draft of the manuscript, and revision and approval of the submitted version.

Kristin Valborg Reinertsen, specialist in oncology, senior consultant and postdoctoral fellow.

The author has completed the ICMJE form and declares the following conflict of interest: She has received research support from the Norwegian Pink Ribbon Foundation.

Breast cancer is the most common cancer among women in Norway. Nine out of ten will become long-term survivors. Being cancer-free does not necessarily mean feeling healthy, and many experience troublesome late effects, such as fatigue, pain and fear of recurrence. General practitioners represent the most important medical support for the majority of these women. This clinical review article summarises up-to-date knowledge about late effects after breast cancer treatment. Non-pharmacological interventions can have a positive effect on many of the most common late effects.

In 2021, more than 4000 women in Norway were diagnosed with breast cancer [\(1\)](#). Most women with breast cancer have localised disease and receive curative surgery, followed by radiation therapy. Many also receive combinations of systemic treatments, such as chemotherapy, endocrine therapy and human epidermal growth factor receptor 2 (HER2) blockade [\(2\)](#). The treatment is effective, and the five-year relative survival rate is 92 % [\(3\)](#). In the Norwegian population, approximately 53 000 people have had or are living with breast cancer, and the number is increasing [\(3\)](#).

Late effects are defined as effects of cancer or adverse effects of treatment that last for one year or more after the end of treatment, or symptoms that are likely caused by the cancer or the treatment and which appear one year or more after completing treatment [\(4\)](#). The risk of severe late effects, such as secondary cancer or heart disease, is low after modern breast cancer treatment. However, a significant proportion of breast cancer survivors will experience one or more less severe late effects that may have a negative impact on their ability to work and quality of life. The purpose of this article is to shed light on the most common late effects after treatment for localised breast cancer. The article is based on subjectively selected systematic reviews, national treatment recommendations, Norwegian research findings and clinical experience.

The most common late effects

Chronic fatigue, cognitive dysfunction, sleep difficulties, pain, fear of recurrence and symptoms of oestrogen deficiency are the most common late effects after breast cancer. Patients who have received radiation therapy to regional lymph nodes have an increased risk of hypothyroidism (5). Breast cancer survivors often experience multiple overlapping and reinforcing symptoms, such as fatigue, pain and sleep difficulties (6). Breast cancer survivors report late effects to a greater extent than other cancer survivors (7). This may be due to the biology or treatment of the disease, but factors related to personality, supportive care needs and coping strategies also play a role (8).

Chronic fatigue is reported by 25–30 % of breast cancer survivors and is characterised by pronounced physical or emotional and/or cognitive fatigue lasting for six months or more, regardless of sleep and activity levels (9). Known risk factors include young age, sleep difficulties, pain and psychiatric comorbidity, and a catastrophising personality (9).

Increasing treatment intensity also appears to increase the risk of fatigue after breast cancer (10). Cognitive fatigue encompasses experiences of impaired memory, difficulty concentrating and/or difficulty finding the correct word (11). These are symptoms that are also part of cognitive dysfunction after cancer (12). More than 50 % of breast cancer survivors report cognitive dysfunction, but objective cognitive dysfunction is only detected in 15–25 % (12). Several factors appear to be associated with cognitive dysfunction. In addition to cancer treatment, genetic predisposition, advanced age and psychiatric comorbidity also seem to contribute (12). Both fatigue and cognitive dysfunction can have a major negative impact on a person's quality of life and ability to work (13–15).

A recent review found that 40 % of breast cancer survivors experience sleep difficulties (16). In a Norwegian study, 30 % of breast cancer survivors had sleep difficulties compared to 18 % of age-matched women without cancer (17). Sleep difficulties are particularly associated with hot flushes, depression and fatigue (16).

Pain is reported by approximately 30 % of breast cancer survivors several years after completing treatment (18). Surgery and radiation therapy can cause locoregional pain, lymphoedema and reduced function in the arm/shoulder (17). Chemotherapy, especially taxanes, can lead to peripheral neuropathy characterised by pain, numbness and tingling, typically in the hands and feet. Fear of cancer recurrence (FCR) is defined as a persistent 'fear, worry or concern relating to the possibility that cancer will come back or progress' (19). While it is natural to experience such concerns following a serious illness, some people develop persistent anxiety and hyper-vigilance towards the possibility of recurrence, leading to an excessive preoccupation with bodily symptoms. In a Norwegian study of survivors of different cancer diagnoses, the highest prevalence of FCR was found among breast cancer survivors, and was particularly associated with young age and caring for children (20). A total of 20–40 % of people struggle with FCR to such a degree that they want help to manage it (21). Anxiety and depression can also occur after breast cancer (22), and young age is also an important risk factor here (23).

Many breast cancer survivors receive adjuvant endocrine treatment for 5–10 years and experience symptoms of oestrogen deficiency. These patients often experience hot flushes, fatigue, sleep difficulties, vulvovaginal atrophy and impaired sexual health (24). Aromatase inhibitors in particular can cause arthralgia and muscle pain.

Follow-up

The Norwegian Breast Cancer Group recommends annual mammography for ten years and follow-up by the specialist health service at least 1, 2 and 5 years after diagnosis, with further assessment depending on age, stage and treatment complexity (2). General practitioners (GPs) are responsible for follow-up beyond the first ten years. The purpose of the annual check-up is to detect recurrence at an early stage, motivate patients to adhere to recommended endocrine treatment, and monitor mammography and thyroid function (Box 1). Additional follow-up must be tailored to the individual's needs.

Box 1 Checklist for routine annual screening

Medical history

Review of cancer history and treatment

Ongoing endocrine treatment? Symptoms of oestrogen deficiency?

Late effects? Pain, fear of recurrence, sleep, fatigue

Ability to work?

Need for rehabilitation measures? Clarify level.

Clinical examination

Both breasts/chest wall, regional lymph node stations

Further symptom-targeted examination

Review of test results

Thyroid tests

Mammography result

In patients with a severe symptom burden, it can be helpful to identify and alert the patient to potential symptom clusters. Improvements in one condition can lead to overall improvement in the symptom burden. The patient should be informed that there is often no single underlying cause for the symptoms, nor targeted treatment, and that they may improve over time. We have found that active listening, providing thorough diagnostic clarification and information, and close follow-up are effective, especially in cases of fatigue and FCR.

Relevant interventions and provision

The interventions that seem to be most effective for late effects after breast cancer are physical activity and cognitive behavioural therapy. This should complement symptomatic treatment of pain, sleep difficulties and symptoms of oestrogen deficiency

as needed. In cases of pronounced symptoms of oestrogen deficiency where non-hormonal symptom-relieving measures are not sufficient, the GP, in close collaboration with the oncologist, can consider pausing, modifying or discontinuing endocrine treatment (2).

Physical activity among cancer survivors is safe and well-tolerated (25). Reviews have reported a clear positive correlation between physical activity and reduced mortality, both for breast cancer-specific mortality and general mortality (26). Physical activity also reduces fatigue (27), pain (28) and cognitive dysfunction (29). It is not known what form of exercise or how much exercise is needed to achieve the best outcome, but most breast cancer survivors can safely follow the Norwegian Directorate of Health's recommendations for the general adult population. Cognitive therapy has been shown to have a positive effect on, for example, FCR (30) and fatigue (31).

There are several rehabilitation services available for breast cancer survivors, ranging from low-threshold services in the primary care service to specialised and interdisciplinary rehabilitation in hospitals or outpatient and inpatient facilities (Figure 1) (32–36). Healthy Life Centres, *Pusterom* (training centres aimed at cancer patients) and physiotherapists with specialised training (AKTIV instructors) offer guidance and physical activity (32–34). Some people may benefit from a referral to a sexologist or psychologist, and these are also available at regional rehabilitation centres.




Figure 1 Provision for breast cancer survivors. Stage 1 is the primary care service, stages 2 and 3 the specialist health service. The services range from low-threshold options suitable for mild symptoms, to specialised interdisciplinary rehabilitation for breast cancer survivors with complex needs and symptoms (32–36).

The Montebello Centre offers general life management courses and courses specifically targeting various late effects (35). Many GPs have specialised training in cognitive therapy and offer this to their own patients. In cases of pronounced, complex and persistent symptoms, referral to a regional late effects outpatient clinic, interdisciplinary pain clinic or residential rehabilitation facility may be appropriate.

In conclusion

Over 90 % of women diagnosed with breast cancer will become long-term survivors. The risk of late effects is high. Many struggle with multiple concurrent symptoms that can negatively impact on their ability to work and quality of life. GPs represent the most important medical support for most breast cancer survivors. Non-pharmacological interventions have the best effect, especially physical activity and cognitive therapy.

These should be initiated alongside symptomatic pharmacological treatment as needed. There are various rehabilitation services available. Good and tailored information about late effects and support from healthcare personnel are important for coping with life as a breast cancer survivor.

This article has been peer-reviewed.

REFERENCES

1. Kreftregisteret. Årsrapport 2021 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for brystkreft.
<https://www.kvalitetsregistre.no/sites/default/files/2022-06/%C3%85rsrapport%202021%20Nasjonalt%20kvalitetsregister%20for%20brystkreft.pdf> Accessed 29.4.2023.
2. Helsedirektoratet. Nasjonalt Handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med brystkreft. Nasjonal Faglig Retningslinje.
<https://www.helsebiblioteket.no/innhold/nasjonal-faglig-retningslinje/brystkreft-handlingsprogram#oppfolging-og-etterkontroll-etter-avsluttet-kurativ-behandling> Accessed 29.4.2023.
3. Norway CRO. Cancer in Norway 2021 - Cancer incidence, mortality, survival and prevalence in Norway. https://www.kreftregisteret.no/globalassets/cancer-in-norway/2021/cin_report.pdf Accessed 29.4.2023.
4. Helsedirektoratet. Seneffekter etter kreftbehandling.
https://www.helsedirektoratet.no/rapporter/seneffekter-etter-kreftbehandling/Seneffekter%20etter%20kreftbehandling.pdf/_/attachment/inline/3d984c2a-7926-4d1aa5f0-06d48fe7c95f:f3e498d059734ff34b013c1c206877e488e95600/Seneffekter%20etter%20kreftbehandling.pdf Accessed 29.4.2023.
5. Solmunde E, Faltie-Jensen AM, Lorenzen EL et al. Breast cancer, breast cancer-directed radiation therapy and risk of hypothyroidism: A systematic review and meta-analysis. *Breast* 2023; 68: 216–24. [PubMed][CrossRef]
6. Bjerkeset E, Röhl K, Schou-Bredal I. Symptom cluster of pain, fatigue, and psychological distress in breast cancer survivors: prevalence and characteristics. *Breast Cancer Res Treat* 2020; 180: 63–71. [PubMed][CrossRef]
7. Jones JM, Olson K, Catton P et al. Cancer-related fatigue and associated disability in post-treatment cancer survivors. *J Cancer Surviv* 2016; 10: 51–61. [PubMed][CrossRef]
8. Bower JE. Cancer-related fatigue—mechanisms, risk factors, and treatments. *Nat Rev Clin Oncol* 2014; 11: 597–609. [PubMed][CrossRef]
9. Reinertsen KV, Loge JH, Brekke M et al. Kronisk tretthet hos voksne kreftoverlevende. *Tidsskr Nor Lægeforen* 2017; 137. doi: 10.4045/tidsskr.17.0040. [PubMed][CrossRef]

10. Abrahams HJG, Gielissen MFM, Schmits IC et al. Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors. *Ann Oncol* 2016; 27: 965–74. [PubMed][CrossRef]
11. Chalder T, Berelowitz G, Pawlikowska T et al. Development of a fatigue scale. *J Psychosom Res* 1993; 37: 147–53. [PubMed][CrossRef]
12. Joly F, Lange M, Dos Santos M et al. Long-Term Fatigue and Cognitive Disorders in Breast Cancer Survivors. *Cancers (Basel)* 2019; 11: 1896. [PubMed][CrossRef]
13. Bøhn SH, Vandraas KF, Kiserud CE et al. Work status changes and associated factors in a nationwide sample of Norwegian long-term breast cancer survivors. *J Cancer Surviv* 2022; 0. doi: 10.1007/s11764-022-01202-2. [PubMed][CrossRef]
14. Ebede CC, Jang Y, Escalante CP. Cancer-Related Fatigue in Cancer Survivorship. *Med Clin North Am* 2017; 101: 1085–97. [PubMed][CrossRef]
15. Vandraas K, Falk RS, Bøhn SKH et al. Work ability 8 years after breast cancer: exploring the role of social support in a nation-wide survey. *Breast Cancer Res Treat* 2022; 193: 685–94. [PubMed][CrossRef]
16. Leysen L, Lahousse A, Nijs J et al. Prevalence and risk factors of sleep disturbances in breast cancersurvivors: systematic review and meta-analyses. *Support Care Cancer* 2019; 27: 4401–33. [PubMed][CrossRef]
17. Dahl AA, Nesvold IL, Reinertsen KV et al. Arm/shoulder problems and insomnia symptoms in breast cancer survivors: cross-sectional, controlled and longitudinal observations. *Sleep Med* 2011; 12: 584–90. [PubMed][CrossRef]
18. Leysen L, Beckwée D, Nijs J et al. Risk factors of pain in breast cancer survivors: a systematic review and meta-analysis. *Support Care Cancer* 2017; 25: 3607–43. [PubMed][CrossRef]
19. Lebel S, Ozakinci G, Humphris G et al. From normal response to clinical problem: definition and clinical features of fear of cancer recurrence. *Support Care Cancer* 2016; 24: 3265–8. [PubMed][CrossRef]
20. Vandraas KF, Reinertsen KV, Kiserud CE et al. Fear of cancer recurrence among young adult cancer survivors-exploring long-term contributing factors in a large, population-based cohort. *J Cancer Surviv* 2021; 15: 497–508. [PubMed][CrossRef]
21. Hodgkinson K, Butow P, Hunt GE et al. Breast cancer survivors' supportive care needs 2-10 years after diagnosis. *Support Care Cancer* 2007; 15: 515–23. [PubMed][CrossRef]
22. Burgess C, Cornelius V, Love S et al. Depression and anxiety in women with early breast cancer: five year observational cohort study. *BMJ* 2005; 330: 702. [PubMed][CrossRef]
23. Tsaras K, Papathanasiou IV, Mitsi D et al. Assessment of Depression and Anxiety in Breast Cancer Patients: Prevalence and Associated Factors. *Asian Pac J Cancer Prev* 2018; 19: 1661–9. [PubMed]

24. Smedsland SK, Vandraas KF, Bøhn SK et al. Sexual activity and functioning in long-term breast cancer survivors; exploring associated factors in a nationwide survey. *Breast Cancer Res Treat* 2022; 193: 139–49. [PubMed][CrossRef]
25. Campbell KL, Zdravec K, Bland KA et al. The Effect of Exercise on Cancer-Related Cognitive Impairment and Applications for Physical Therapy: Systematic Review of Randomized Controlled Trials. *Phys Ther* 2020; 100: 523–42. [PubMed][CrossRef]
26. Friedenreich CM, Stone CR, Cheung WY et al. Physical Activity and Mortality in Cancer Survivors: A Systematic Review and Meta-Analysis. *JNCI Cancer Spectr* 2019; 4: pkz080. [PubMed][CrossRef]
27. van Vulpen JK, Peeters PH, Velthuis MJ et al. Effects of physical exercise during adjuvant breast cancer treatment on physical and psychosocial dimensions of cancer-related fatigue: A meta-analysis. *Maturitas* 2016; 85: 104–11. [PubMed][CrossRef]
28. Irwin ML, Cartmel B, Gross CP et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. *J Clin Oncol* 2015; 33: 1104–11. [PubMed][CrossRef]
29. Hartman SJ, Nelson SH, Myers E et al. Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: The memory & motion study. *Cancer* 2018; 124: 192–202. [PubMed][CrossRef]
30. Sharpe L, Turner J, Fardell JE et al. Psychological intervention (ConquerFear) for treating fear of cancer recurrence: mediators and moderators of treatment efficacy. *J Cancer Surviv* 2019; 13: 695–702. [PubMed][CrossRef]
31. Haussmann A, Schmidt ME, Illmann ML et al. Meta-Analysis of Randomized Controlled Trials on Yoga, Psychosocial, and Mindfulness-Based Interventions for Cancer-Related Fatigue: What Intervention Characteristics Are Related to Higher Efficacy? *Cancers (Basel)* 2022; 14: 2016. [PubMed][CrossRef]
32. Aktiv mot kreft. Pusterommet. <https://aktivmotkreft.no/vart-arbeid/pusterom/> Accessed 10.3.2023.
33. Helsenorge. Kreft og rehabilitering. <https://www.helsenorge.no/sykdom/kreft/rehabilitering/#rehabiliteringstilbud-i-kommunender-du-bor> Accessed 10.3.2023.
34. Aktiv mot kreft. Her finner du landets AKTIVinstruktører. <https://aktivmotkreft.no/aktivinstruktor> Accessed 10.3.2023.
35. Montebellosenteret. Lær å leve med endringer som følge av kreft. <https://www.montebellosenteret.no/> Accessed 10.3.2023.
36. Kreftforeningen. Vardesenteret. <https://kreftforeningen.no/vardesenteret/> Accessed 10.3.2023.

Received 7.1.2023, first revision submitted 10.3.2023, accepted 29.4.2023.

Published under open access CC BY-ND. Downloaded from tidsskriftet.no 14 July 2026.